NCT06502613 Idiopathic Scoliosis New Onset and Melatonin Phase Delay in Children
| NCT ID | NCT06502613 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Second Affiliated Hospital of Wenzhou Medical University |
| Condition | Scoliosis Idiopathic |
| Study Type | OBSERVATIONAL |
| Enrollment | 956 participants |
| Start Date | 2024-08-01 |
| Primary Completion | 2027-07-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 956 participants in total. It began in 2024-08-01 with a primary completion date of 2027-07-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aimed to investigate the prevalence and clinical significance of melatonin phase delay in children with new onset and progressive idiopathic scoliosis (IS).
Eligibility Criteria
Inclusion Criteria: * Collect saliva according to standards and complete melatonin testing * Complete scoliometer or X-ray assess scoliosis * Skeletally immature (Risser Sign 0-3) * Age between 6 and 15 * Patients can understand and complete the MEQ-5, PSQ, and PSQI Questionnaire at baseline and follow-up visits * Informed Consent Form signed by subject or the guardian Exclusion Criteria: \-
Contact & Investigator
Aimin Wang, MD
STUDY CHAIR
Second Affiliated Hospital of Wenzhou Medical University
Frequently Asked Questions
Who can join the NCT06502613 clinical trial?
This trial is open to participants of all sexes, aged 6 Years or older, up to 15 Years, studying Scoliosis Idiopathic. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06502613 currently recruiting?
Yes, NCT06502613 is actively recruiting participants. Contact the research team at Xiangyangwang@wmu.edu.com for enrollment information.
Where is the NCT06502613 trial being conducted?
This trial is being conducted at Wenzhou, China.
Who is sponsoring the NCT06502613 clinical trial?
NCT06502613 is sponsored by Second Affiliated Hospital of Wenzhou Medical University. The principal investigator is Aimin Wang, MD at Second Affiliated Hospital of Wenzhou Medical University. The trial plans to enroll 956 participants.